Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Area of Science:

• Virology
• Infectious Diseases
• Drug Discovery

Background:

• Ebola Virus Disease (EVD) is a highly lethal infectious disease with a significant global public health impact.
• The 2013-2016 West Africa outbreak underscored the urgent need for effective EVD treatments.
• Studying EVD antivirals in vitro has been challenging due to biosafety level-4 (BSL-4) containment requirements.

Purpose of the Study:

• To highlight the importance of developing tools for studying Ebola virus antivirals.
• To discuss the role of surrogate models in advancing EVD research.
• To emphasize the potential of integrated screening and design approaches for EVD drug development.

Main Methods:

• Development of surrogate models (viral pseudotypes, Ebola virus-like particles) for BSL-2 research.
• Utilizing these models to study the Ebola virus life cycle and viral entry.
• Combining surrogate systems with high-throughput screening, genetic screens, rational drug design, and drug repurposing.

Main Results:

• Surrogate models have significantly improved understanding of the Ebola virus life cycle.
• These models have accelerated the identification of antiviral compounds targeting viral entry.
• The use of surrogate systems has enabled antiviral screening outside of BSL-4 containment.

Conclusions:

• Surrogate systems are invaluable for studying Ebola virus entry and identifying antivirals.
• Integrated approaches combining surrogate systems with advanced screening and design methods are crucial for EVD treatment development.
• Continued research using these tools promises to yield effective therapies for Ebola Virus Disease.